EGFR and cancer: EGFR tyrosine kinase inhibitors (EGFR-TKIs) block the cellular functions mediated by EGFR kinase signaling in non-small cell lung cancer, but they also activate inactive EGFR in autophagy, which may provide a survival advantage and induce TKI resistance in cancer (108).